Clinical Trials
Both MDMA and psilocybin are in the process of being researched and approved for therapeutic use to treat a number of conditions, including PTSD, depression, anxiety, and addiction. In addition to supporting regulatory change via our clinical advisory board, Numinus is conducting clinical trials with both substances, and preparing for the eventual roll-out of these therapies to the general public.
Compassionate Access Trial
MDMA for PTSD
Numinus has partnered with MAPS for a single-arm, open-label, compassionate access trial for MDMA-assisted therapy for PTSD.
Compassionate Access Trial
Psilocybin for Substance Use Disorder
Numinus has partnered with Syreon Corporation to pursue a single-arm, open-label compassionate access trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders.
Get notified when these treatments become available.
Join our early interest list for MDMA and Psilocybin Assisted Psychotherapy and we’ll keep you updated on progress.